The Reduced Form of Coenzyme Q10 Improves Glycemic Control in Patients With Type 2 Diabetes

Researchers have conducted an open label study to examine the clinical effects of supplementation of the reduced form of CoQ10, Ubiquinol, in addition to conventional glucose-lowering agents in patients with type 2 diabetes.

The effect of Ubiquinol on blood pressure, lipid profile, glycemic control, oxidative stress, and inflammation were examined before and after Ubiquinol supplementation.The results of our study are consistent with the suggestion that the supplementation of Ubiquinol in subjects with type 2 diabetes, in addition to conventional antihyperglycemic medications, improves glycemic control by improving insulin secretion without any adverse effects.

Journal: BioFactors

Authors: MoritoMezawa, Minoru Takemoto, ShunichiroOnishi, Ryoichi Ishibashi, Takahiro Ishikawa, Masaya Yamaga, Masaki Fujimoto, Emiko Okabe, Peng He, Kazuki Kobayashi, and KoutaroYokote

Department: Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Chiba, Japan

Abstract link: https://www.ncbi.nlm.nih.gov/pubmed/22887051

Contact